Focal adhesion kinase inhibitors are potent anti-angiogenic agents

A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer

(2011) Steven N. Hochwald et al.   CELL CYCLE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model

(2010) Cedo M Bagi et al.   CANCER BIOLOGY & THERAPY

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

(2010) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Endothelial FAK is required for tumour angiogenesis

(2010) Bernardo Tavora et al.   EMBO Molecular Medicine

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer

(2010) Alexander Schultze et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis

(2009) Vita M Golubovskaya et al.   BMC CANCER

Signal transduction by focal adhesion kinase in cancer

(2009) Jihe Zhao et al.   CANCER AND METASTASIS REVIEWS

Targeting focal adhesion kinase signaling in tumor growth and metastasis

(2009) Joerg Schwock et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis

(2009) Alexander Schultze et al.   INVESTIGATIONAL NEW DRUGS

Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors

(2008) Cedo M. Bagi et al.   CANCER

TAE226 Inhibits Human Neuroblastoma Cell Survival

(2008) Elizabeth A. Beierle et al.   CANCER INVESTIGATION

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

(2008) W. G. Roberts et al.   CANCER RESEARCH

A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth

(2008) Vita M. Golubovskaya et al.   JOURNAL OF MEDICINAL CHEMISTRY